Genmab A/S (OTCMKTS:GNMSF) Share Price Passes Below Two Hundred Day Moving Average – What’s Next?

Genmab A/S (OTCMKTS:GNMSF)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $305.26 and traded as low as $275.30. Genmab A/S shares last traded at $275.30, with a volume of 8 shares trading hands.

Genmab A/S Stock Performance

The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The stock has a fifty day moving average price of $312.42 and a two-hundred day moving average price of $305.26. The company has a market cap of $16.95 billion, a P/E ratio of 17.78 and a beta of 0.92.

Genmab A/S (OTCMKTS:GNMSF) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.10 by ($2.55). The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.05 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.